Related Experiment Videos

Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?

P K Jacobsen1, L Tarnow, H-H Parving

  • 1Steno Diabetes Center, Gentofte, Denmark. pkjacobsen@dadlnet.dk

Kidney International
|April 14, 2006
PubMed

Insights

Individual responses to diabetic nephropathy treatments vary greatly. The angiotensin-converting enzyme (ACE) insertion/deletion polymorphism significantly impacts the disease

Area of Science:

  • Nephrology
  • Genetics
  • Pharmacogenomics

Background:

  • Diabetic nephropathy has a poor prognosis despite current therapies.
  • Treatment response varies significantly among individuals with this condition.
  • Both genetic and non-genetic factors influence therapeutic efficacy.

Purpose of the Study:

  • To summarize the impact of the angiotensin-converting enzyme (ACE) insertion/deletion polymorphism on diabetic nephropathy.
  • To highlight the role of genetic factors in treatment response.

Main Methods:

  • This is a commentary, not an experimental study.
  • Literature review and synthesis of existing research on ACE polymorphism and diabetic nephropathy.

Main Results:

  • The ACE insertion/deletion polymorphism is a key factor influencing the initiation and progression of diabetic nephropathy.
  • This genetic variation contributes to the interindividual differences in treatment response.

Conclusions:

  • Understanding the ACE gene polymorphism is crucial for personalized renoprotective strategies.
  • Targeting ACE-related pathways may offer improved outcomes for diabetic nephropathy patients.

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...